1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Micro Labs Acquires Swipha, to Strengthen Its Presence in Nigeria, Africa

18 Oct 2024
Admin
News Article

Micro Labs Acquires Swipha, to Strengthen Its Presence in Nigeria, Africa

Overview

Micro Labs, Karnataka’s pharma major has acquired Swiss Pharma Nigeria Limited (Swipha), a leading pharmaceutical company in Nigeria. This marks its efforts to further bolster its presence in in Nigeria and across Africa.

Staff of Swipha post acquisition- Disclosing officially on the acquisition to a media house in Africa, the company said that all the staff of Swipha would be retained.

About the Company: Micro Labs

The Bengaluru-based Micro Labs is a fully integrated pharmaceutical company primarily engaged in the manufacturing and marketing of branded generic formulations in India and emerging markets.
The company specialises in manufacturing of high-quality, affordable generic medicines across a diverse range of therapeutic areas with several formulations listed on WHO pre-qualification list including but not limited to anti-malaria.

From the MD: Micro Labs Nigeria

According to Hemant Sharma, managing director, Micro Labs in Nigeria and now chairman of Swipha, the company’s portfolio includes cardiology, diabetology, pain management, dermatology, ophthalmology, veterinary, neurology.

Micro Labs: International Offices

With a network of 14 formulation plants, including an injectable unit and a bulk drug facility, Micro Labs has The company has established international offices in the United States, the United Kingdom, Germany, Australia, and Nigeria, with representative offices in emerging markets.

Company Functioning in Nigeria

In Nigeria, the pharma company operates through Micro Nova Pharmaceutical Ind. Limited, with operations spanning over a decade in the Nigeria pharmaceutical industry space and has risen as market leader in specialised therapeutic segments.

Swiss Pharma Nigeria Limited (Swipha)

Swipha on the other hand is a leading pharmaceutical company incorporated in 1976 dedicated to providing high-quality, affordable medicines to improve healthcare outcomes in Nigeria and Africa.
Swipha is engaged in manufacturing, marketing, and distribution of high quality, affordable, branded generics, and INN.
The portfolio includes therapeutic classes of central nervous system, anti-malaria, anti-infectives, cardiovascular system, and anti-diabetic, stated Micro in its disclosure to the media house in Africa.
1st of its kind- Swipha is also first in Nigeria, West and Central Africa to attain WHO pre-qualification for zinc (anti-diarrhoea) and sulfadoxine, pyrimethamine (anti-malaria) drugs.

From the MD: Micro Labs Nigeria (Continu….)

Sharma said “The acquisition will create significant value by consolidating both companies’ portfolios. The aim is providing affordable, quality medicines to the people of Nigeria and Africa and as well expand the range of antimalarial, anti-infectives cardio and metabolism among others.
Noting that the acquisition will provide more comprehensive treatment options, Sharma said, “Swipha’s distribution network, CRM, will improve supply chain efficiency, while its WHO-approved plant will enable Micro Labs to support manufacturing and export products to neighbouring countries.

From the Company

“With Micro Labs presence across the entire pharmaceutical value chain – research and development, active pharmaceutical ingredients (APIs), finished formulations, the synergies that will reduce costs. Both companies are known for their quality and business acumen, making this acquisition a strategic move to leverage their combined strengths for greater success,” said the company disclosure.